Edition:
United States

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

3.70USD
10:48am EDT
Change (% chg)

$-0.10 (-2.63%)
Prev Close
$3.80
Open
$3.79
Day's High
$3.79
Day's Low
$3.70
Volume
1,554
Avg. Vol
11,533
52-wk High
$10.67
52-wk Low
$3.10

Latest Key Developments (Source: Significant Developments)

Novelion Therapeutics Reports Gaap Net Loss In Q4 Of 2017
Thursday, 15 Mar 2018 05:17pm EDT 

March 15 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $38.9 MILLION VERSUS $13.6 MILLION.GAAP NET LOSS IN Q4 OF 2017 WAS $24.6 MILLION COMPARED TO GAAP NET LOSS OF $19.9 MILLION DURING SAME PERIOD IN 2016.  Full Article

Novelion Therapeutics Says Its Unit Has Entered Into A New Secured Financing Facility
Thursday, 15 Mar 2018 05:09pm EDT 

March 15 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS SAYS ITS UNIT HAS ENTERED INTO A NEW SECURED FINANCING FACILITY WITH AFFILIATES OF SARISSA CAPITAL AND BROADFIN CAPITAL.NOVELION THERAPEUTICS SAYS THE FINANCING FACILITY PROVIDES FOR A $20 MILLION TERM LOAN TO CO'S UNIT AEGERION PHARMACEUTICALS.NOVELION THERAPEUTICS SAYS AEGERION PLANS TO USE THE CAPITAL TO SUPPORT ONGOING DEVELOPMENT OF METRELEPTIN IN ADDITIONAL INDICATIONS.NOVELION - AEGERION'S OBLIGATIONS UNDER FACILITY ARE SECURED BY SUBSTANTIALLY ALL OF ITS ASSETS, INCLUDING IP RIGHTS OF MYALEPT AND JUXTAPID.NOVELION THERAPEUTICS SAYS THE LENDERS WERE COLLECTIVELY ISSUED WARRANTS TO PURCHASE ABOUT 1.8 MILLION COMMON SHARES OF NOVELION.NOVELION THERAPEUTICS - WARRANTS HAVE AN EXERCISE PRICE EQUAL TO $4.40 PER SHARE.  Full Article

Novelion Says U.S. District Court Judge Sentenced Unit Aegerion Pharmaceuticals
Tuesday, 30 Jan 2018 05:51pm EST 

Jan 30 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS INC - ANNOUNCED THAT A U.S. DISTRICT COURT JUDGE HAS SENTENCED NOVELION SUBSIDIARY AEGERION PHARMACEUTICALS.NOVELION THERAPEUTICS INC - SENTENCE IMPOSED BY COURT IS PART OF AEGERION'S GLOBAL SETTLEMENT OF INVESTIGATIONS BY U.S. DOJ, U.S. SEC.NOVELION THERAPEUTICS - COURT DECIDED NOT TO IMPOSE CRIMINAL FINE ON UNIT, ESTABLISHED RESTITUTION FUND OF $7.2 MILLION TO BE PAID IN PARTS OVER 3 YEARS.NOVELION THERAPEUTICS-AEGERION'S GLOBAL SETTLEMENT HAS SERIES OF AGREEMENTS WHICH, IF APPROVED, TO RESULT IN ABOUT $40.1 MILLION PENALTY TO BE PAID OVER 3 YRS.NOVELION THERAPEUTICS - AS PART OF SETTLEMENT, AEGERION ALSO ENTERED 5-YEAR CORPORATE INTEGRITY AGREEMENT WITH DEPARTMENT OF HEALTH AND HUMAN SERVICES.  Full Article

Edgepoint Investment Group Reports 10.6 Pct Passive Stake In Novelion Therapeutics
Friday, 8 Dec 2017 11:31am EST 

Dec 8 (Reuters) - Novelion Therapeutics Inc ::EDGEPOINT INVESTMENT GROUP INC REPORTS 10.6 PERCENT PASSIVE STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 30 - SEC FILING.  Full Article

Novelion Therapeutics Appoints Michael Price As CFO
Monday, 4 Dec 2017 08:30am EST 

Dec 4 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.NOVELION THERAPEUTICS INC - ‍GREGORY PERRY HAS RESIGNED AS CFO TO PURSUE OTHER OPPORTUNITIES, AND WILL REMAIN WITH COMPANY UNTIL DECEMBER 31, 2017​.NOVELION THERAPEUTICS INC - ‍APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 4, 2017​.  Full Article

Novelion Therapeutics provides update on agreement between Aegerion Pharma and U.S. Department of Justice
Tuesday, 21 Nov 2017 08:30am EST 

Nov 21 (Reuters) - Novelion Therapeutics Inc :Novelion Therapeutics provides update on agreement between Aegerion Pharmaceuticals and U.S. Department of Justice.Novelion Therapeutics - ‍district judge William Young rejected Aegerion Pharmaceuticals' amended criminal plea agreement which was negotiated with U.S. DOJ.Novelion Therapeutics Inc - ‍company, in consultation with its outside counsel, is currently evaluating its options and next steps​.  Full Article

Novelion Therapeutics says CEO resigns, posts Q3 results
Thursday, 9 Nov 2017 08:28am EST 

Nov 9 (Reuters) - Novelion Therapeutics Inc :Novelion Therapeutics reports third quarter 2017 financial results and announces leadership change.Sees FY 2017 revenue $135 million to $145 million.Q3 revenue $28.7 million.Novelion Therapeutics Inc - ‍Company reiterates FY 2017 guidance for total net revenues of $135-$145 million​.Novelion Therapeutics Inc - ‍Chief Executive Officer Mary Szela has resigned for personal reasons, effective immediately​.Novelion Therapeutics Inc - ‍Board announced creation of an interim office of chief executive officer​.Qtrly loss per share $2.67 ‍​.Novelion Therapeutics Inc - ‍Continues to anticipate EMA approval for Metreleptin​ in first half of 2018.  Full Article

Novelion Therapeutics Q2 revenue $40.9 million
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Novelion Therapeutics Inc :Novelion Therapeutics reports second quarter 2017 financial results.Q2 revenue $40.9 million.Sees FY 2017 revenue $135 million to $145 million.Sees FY total net revenues between $135 million and $145 million,.Qtrly loss per share $1.15.  Full Article

Novo Nordisk: Novelion CEO leaves board to avoid potential conflict of interest
Tuesday, 16 May 2017 10:18am EDT 

May 16 (Reuters) - Novo Nordisk ::Says Mary Szela steps down from Novo Nordisk's board of directors with immediate effect."The decision follows changed strategic focus for Novelion Therapeutics, a US-based rare disease company, where Ms Szela serves as CEO, which could lead to a potential conflict of interest".  Full Article

Novelion Therapeutics reports Qtrly loss per share $1.67
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Novelion Therapeutics Inc : :Novelion Therapeutics reports first quarter 2017 financial results.Sees FY 2017 revenue $155 million to $165 million.Q1 revenue $30 million.Qtrly loss per share $1.67.Q1 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.  Full Article